RecruitingNot ApplicableNCT02812212
CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome
Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome
Sponsor
Centre Hospitalier Universitaire de la Réunion
Enrollment
75 participants
Start Date
Nov 28, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
Cortical transit time on diuretic renogram as an early marker of significant obstruction in antenatally detected uretero-pelvic junction syndrome
Eligibility
Min Age: 4 WeeksMax Age: 8 Weeks
Inclusion Criteria7
- Infants:
- Aged of 4 to 8 weeks of life
- Presenting an ureteropelvic junction obstruction (UPJO) detected before birth by ultrasound
- Presenting an UPJO, defined by an Antero-Posterior Renal Pelvic Diameter greater or equal to 15 mm, confirmed by ultrasound post-natally between the 1st and 15th day of life
- Presenting a unilateral UPJO
- whose legal representatives have provided a signed free and informed written consent for their infant's participation
- whose at least one of his legal representative is affiliated to national social security
Exclusion Criteria10
- Infants presenting:
- A bilateral UPJO
- An ureteral dilatation
- An associated contralateral uropathy
- A solitary kidney
- A renal insufficiency
- Severe associated disabilities ( ie polymalformation syndromes)
- A concomitant participation in another trial
- A contraindication to furosemide (acute renal insufficiency, hepatic encephalopathy, hypovolemia or dehydration, severe hypokalemia, severe hyponatremia)
- A contraindication to the radionuclide marker (hypersensitivity to the active substance or to excipients)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEultrasonography
bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
DEVICEdiuretic renography
diuretic renography to measure the cortical transit time.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02812212